AffiliationCRC Department of Medical Oncology, University of Manchester and Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK.
MetadataShow full item record
AbstractIt is now clear that many human tumour antigens can be recognised by the immune system. These tumour antigens can be classified into several groups including cancer-testis, differentiation, tissue specific, over-expressed, and viral-associated antigens. In many cases, there is a known molecular basis of carcinogenesis which provides the explanation for the differentiated expression of these antigens in tumours compared with normal cells. Improved understanding of the biology of the immune response, particularly of immune recognition and activation of T-cells, allow better design of vaccines. Pre-clinical comparative studies allow evaluation of optimal vaccine strategies which can then be delivered to the clinic. Currently, a range of cancer vaccines are being tested including those using tumour cells, proteins, peptides, viral vectors, DNA or dendritic cells. Ultimately, this research should give rise to an entirely new modality of cancer treatments.
CitationCancer vaccines and immunotherapy. 2002, 62:149-62 Br. Med. Bull.
JournalBritish Medical Bulletin
- Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.
- Authors: Jäger D, Jäger E, Knuth A
- Issue date: 2001 Sep
- [Identification of cancer antigens of relevance for specific cancer immunotherapy].
- Authors: van den Eynde B
- Issue date: 2001
- [Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer].
- Authors: Punt CJ, de Vries IJ, Mulders PF, Adema GJ, Figdor CG
- Issue date: 1999 Nov 27
- Current developments in cancer vaccines and cellular immunotherapy.
- Authors: Ribas A, Butterfield LH, Glaspy JA, Economou JS
- Issue date: 2003 Jun 15
- Development of optimized cryptic peptides for immunotherapy.
- Authors: Menez-Jamet J, Kosmatopoulos K
- Issue date: 2009 Feb